Skip to content

Released May 9, 2017, after the close

10-Q filed May 9, 2017, 39 days after period end · 0001232524-17-000111

Q1 2017 · 10-Q
Revenue$376.05M+11.9% vs Q1 2016−5.2% vs Q4 2016
Net Income$86.51M+14.1% vs Q1 2016−25.9% vs Q4 2016
EPS Diluted$1.41+16.5% vs Q1 2016−26.2% vs Q4 2016
Gross Profit$348,613,000+12.3%
Operating Income$136,140,000+12.4%
Operating Cash Flow$164,540,000+8.5%
Free Cash Flowderived$160,966,000+7.9%
Margins · derived
Gross margin92.7%+0.3 pt vs Q1 2016
Operating margin36.2%+0.1 pt vs Q1 2016
Net margin23.0%+0.4 pt vs Q1 2016

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2017Q1 2016Q1 2015Q1 2014
Revenue$376.05M$336.01M$309.30M$246.92M
Net Income$86.51M$75.81M$70.70M-$92.65M
EPS Diluted$1.41$1.21$1.12-$1.58

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR